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INTRODUCTION
Hepatocellular carcinoma (HCC) is a universal malignant 
tumor with poor prognosis. It is the third cause of cancer 
mortality after lung cancer and stomach cancer globally, also in 
Korea [1]. Although there have been significant developments in 
therapies for HCC including surgery, transarterial chemoemboli-
zation, radiofrequency thermal ablation, and multikinase inhi-
bitors (sorafenib, sunitinib, etc.), HCC remains a lethal disease 
[2,3]. Accordingly, discovery of new therapeutic targets and 
biomarkers for early diagnosis and prognosis prediction of HCC 
with development of gene and expression analysis comes to the 
forefront [4-6].
Sal-like protein 4 (SALL4) is a human homolog to Drosophaila 
spalt. In humans, SALL4 is one of several transcription factors 
which are a valuable part of the self-renewal of embryonic 
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stem cells as well as in embryonic development [7-9]. Many 
published studies showed SALL4 is an oncogene in leukemia 
and other various types of cancers like non–small-cell lung 
cancers (NSCLC), breast cancer, and testicular germ cell tumors 
[10-12]. In the liver, elevated SALL4 was found in fetal liver, and 
SALL4 gradually diminishes during development [13]. Yong et 
al. [14] showed unique expression patterns of SALL4 in human 
livers at various stages – expressed as an oncofetal protein in 
HCC, activated in liver of fetus, and inactivated in liver of adult.
Recently, outstanding studies have suggested SALL4, an 
oncofetal gene, as a prognosis biomarker in HCC. With that, 
previous studies that were published showed SALL4 expression 
in HCC patients could potentially be a new treatment target for 
HCC. However, there were many debates in study groups on the 
difference in terms of etiologic causes between Western and 
Asian HCC and detection method. Hence, general application 
of SALL4 for HCC is needed to confirm the diagnostic and 
therapeutic efficacy of SALL4 [14-17].
Therefore, we tried to verify the features of SALL4 immuno-
reactivity and its clinical correlation in Korean HCC patients. 
We will use SALL4 as a new therapeutic target for HCC based 
on this study.
METHODS
Patients and tissue specimens
A total of 213 patients with HCCs with complete clinico-
pathologic data were collected. Patients were underwent 
curative surgery at the department of surgery, Hanyang 
University Seoul Hospital between January 1991 and September 
2013. Medical records were reviewed and characteristic data 
(age, sex), pathologic data (tumor size, tumor number, histologic 
grade, vascular invasion, perineural invasion), and clinical data 
(α-FP, survival, ascite, albumin, bilirubin, encephalopathy, 
prothrombin time) were extracted. 
Tissue microarray construction
The pathologist (S.S.P.) reviewed the histology of each case, 
and selected the representative, properly fixed, and viable 
areas for tissue microarray (TMA) construction. Single 2.0-mm 
tissue cores were sampled from donor blocks and transferred to 
recipient blocks.
Immunohistochemical staining
The 4-µm-thick tissue sections from TMA blocks were 
deparaffinized with xylene and rehydrated in a graduated 
series of ethanol. For heat-induced antigen retrieval, the 
following conditions were applied for optimization: autoclave 
heating at 100oC for 30 minutes; and microwave heating for 
12 minutes in pH 6.0 sodium citrate buffer. 3% H2O2 was used 
for blocking endogenous peroxidase activity. TMA slides were 
incubated with anti-SALL4 antibody (dilution factor 1:200, 
clone 6E3, Sigma-Aldrich, St Louis, MO, USA) at 4oC overnight, 
and then incubated with antirabbit secondary antibody 
(Dako, Carpinteria, CA, USA) at room temperature for 30 
minutes. 3,3 -´Diaminobenzidine was used as a chromogen for 
visualization.
Interpretation of SALL4 expression
The immunohistochemical staining slides were interpreted 
by 2 pathologists who were blinded to clinical data. The 
interpretation was based on a semiquantitative system; the 
staining intensity and proportion. Staining intensity was scored 
as 0 (negative), 1 (weak), 2 (intermediate), 3 (strong). Staining 
proportion was scored as 0 (<10%), 1 (11%–25%), 2 (26%–50%), 
3 (51%–75%), 4 (76%–100%) according to the percentage of 
immunoreactive tumor cells. The final score as immunoreactive 
score (IRS) was calculated by multiplying intensity score by 
proportion score (Fig. 1). xPositive SALL4 expression was 
defined as tumor cells having nuclear staining with minimal 
background and 1 or more IRS.
Statistical analysis
The appropriate statistical analysis was used with IBM SPSS 
ver. 18.0 (IBM Co., Armonk, NY, USA). The correlation between 
the SALL4 expression and tumor size, α-FP was evaluated using 
Fig. 1. The representative sections of Sal-like protein 4 immunohistochemical staining in hepatocellular carcinoma. The nuclei 
of tumor cells shows negative (A), intermediate (B), and strong (C) immunoreactivity. No hepatocellular carcinoma revealed 
strongly positive immurnostaining, which is shown in germ cell tumor (×400).
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Student t-test. The chi-square test was used to analyze the 
relationship between SALL4 expression and the clinical and 
pathological characteristics, including patient sex, histologic 
grade, American Joint Committee on Cancer (AJCC) stage, 
Child-Pugh score, Okuda stage, perineural invasion, and blood 
vessel invasion. The survival analyses were obtained by Kaplan-
Meier methods, and log-rank test was used to compare their 
differences. A difference of P-value less than 0.05 between 
groups was considered significant.
RESULTS
Demographic and clinical data of the patients
Table 1 summarizes the general characteristics of HCC pa-
tients. Of the 213 patients who were included in this TMA 
analysis, 167 patients (78.4%) were male and 46 patients 
(21.6%) were female. The mean age was 55.39 years (range, 
15–87 years) and the mean survival was 49.97 months (range, 
0–278 months). The average tumor size of the largest tumor in 
patients were 4.76 cm (range, 0.7–22 cm) and the majority (n = 
176, 82.6%) of patients had single tumor. The mean serum α-FP 
level was 715.11 ng/mL (range, 1–11,000 ng/mL).
Table 2 summarizes the clinicopathologic characteristics of 
HCC patients. Among 213 patients with available tumor grading 
information (Edmondson and Steiner Grade), 13 patients (6.1%) 
were grade 1, 74 patients (34.7%) were grade 2, 101 patients 
(47.4%) were grade 3, and 19 patients (8.9%) were grade 4. 
The Child-Pugh score was marked for all patients who were 
included in this study, among whom, 200 patients (93.9%) were 
stage A, and the other 13 patients (6.1%) were stage B. The AJCC 
staging information was in use for 211 patients: 119 patients 
(55.9%) were stage I, 45 patients (21.1%) were stage II, 40 patients 
(18.8%) were stage III, and 7 patients (3.3%) were stage IV. The 
Okuda stage was available for all patients: 175 patients (82.2%) 
were stage I, and the other 38 patients (17.8%) were stage II. 
Vessel invasion was seen in 86 patients (40.4%), and perineural 
invasion was seen in 5 patients (2.3%). 
Immunohistochemical staining for SALL4 in human 
HCC tissues
Using the semiquantative scoring system for SALL4 as 
described above, among 213 HCC TMA specimens, 50 (23.5%) 
showed scores of ≥1 (range, 1 to 9). According to the method 
of antigen retrieval, there was difference in staining intensity; 
Autoclave heating at 100oC for 30 minutes (50 cases) increased 
the positive expression cases than heating for 12 minutes (2 
cases) in sodium citrate buffer (Fig. 2).
Correlation between SALL4 expression and clinico-
pathological parameters in HCC
It demonstrated that the SALL4-positive HCCs had consi-
derably higher tumor grade (P < 0.001) compared with SALL4-
negative HCCs. On the clinicopathologic analyses, relevance 
between SALL4 and clinicopathologic features were not found 
Table 1. General characteristics of hepatocellular carcinoma 
patients
Characteristic Value
No. of total cases 213
Sex
   Male:female 167:46
Age (yr), mean (range) 55.39 (15–87)
Survival (mo), mean (range) 49.97 (0–278)
Largest tumor size (cm), mean (range) 4.76 (0.7–22)
Tumor number,
   Single:multiple 176:37
α-FP, mean (range) 715.11 (1–11,000)









   Male 37 130
   Female 13 33
Histologic grade <0.001
   G1 0 13
   G2 5 69
   G3 37 64
   G4 6 13
AJCC stage 0.210
   I 25 94
   II 12 33
   III (a, b, c) 5, 5, 0 19, 6, 5
   IV (a, b) 2, 1 1, 3
Child-Pugh score 0.042
   A 50 150
   B 0 13
   C 0 0
Okuda stage 0.292
   I 44 131
   II 6 32
   III 0 0
Vessel invasion 0.242
   Present 24 62
   Not identified 24 96
Perineural invasion 0.331
   Present 2 3
   Not identified 46 155
Tumor size (cm), mean ± SD 4.96 ± 3.46 4.69 ± 3.68 0.643
α-FP (log), mean ± SD 2.57 ± 0.93 1.55 ± 0.95 <0.001
SALL4, Sal-like protein 4; AJCC, American Joint Committee on 
Cancer; SD, standard deviation.
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in microscopic and macroscopic vessel invasions, perineural 
invasions, but SALL4 and α-FP correlated significantly (P = 
0.002) (Table 2).
Positive SALL4 expression is a prognostic marker of 
overall survival in large HCC
Following the univariate analysis, SALL4 immunoreactivity 
was associated with prognosis. There was no considerable 
correlation with SALL4 and prognosis. However, survival 
analysis showed positive correlation with largest tumor size (P 
= 0.005), and SALL4 immunoreactivity in T3 and T4 HCC were 
correlated with poor prognosis (Fig. 3).
DISCUSSION
 HCC is a lethal disease with a high mortality among various 
cancers [18]. In this study, we show the features of SALL4 
immunoreactivity and its clinical correlation in Korean HCC 
patients.
SALL4 immunoreactivity (defined as IRS ≥1) was seen in 50 
cases of a total 213 cases in our analysis. In this study, histologic 
grade and α-FP were correlated significantly with SALL4. 
Correlations between SALL4 and clinicopathologic factors were 
not seen in AJCC stage, Okuda stage, vessel invasion, perineural 
invasion, or tumor size. In the survival analysis, positive 
correlation with large tumor size, histologic grade, and SALL4 
immunoreactivity in T3 and T4 were correlated with poor 
prognosis. 
From these results, we have several significant clinical 
Fig. 2. Comparison of Sal-like protein 4 immunostaining for different antigen retrieval methods. Strong positive staining in 
the nuclei of tumor cells of germ cell tumor (positive control) is observed in section treated with 30-minute autoclave heating 
(D), whereas intermediate staining is observed in the consecutive section treated with 12-minute microwave heating (A). Two 
representative sections from hepatocellular carcinoma also shows an enhanced immunoreactivity in sections treated with 
30-minute autoclave heating (E, F), compared to 12-minute microwave method (B, C) (×400).
D E F
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Fig. 3. Survival curve according to Sal-like protein 4 (SALL4) 
expression in large hepatocellular carcinoma (T3 and T4). 
Kaplan-Meier survival curve with log-rank test reveals that 
patients with SALL4-positive tumor have worsen overall 
survival.
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suggestions. SALL4 immunohistochemisty correlates with 
aggressive progress and poor prognosis of HCC in some cases. 
Therefore, it shows the potency of SALL4 as a prognostic 
biomarker in HCC, and furthermore as a therapeutic target for 
HCC.
However, there are some limitations in this study. First, the 
TMA of HCC in this study consisted of resected specimens of 
HCC patients from only one center in Korea without a database 
of underlying disease. Some studies published previously 
showed that there were differences of SALL4 expression 
according to ethnicity or underlying disease like HBV [14,15]. 
Second, immunohistochemical staining method is slightly 
different from previous studies in areas of antigen retrieval 
and so on. Also, interpretation of SALL4 expression includes 
injection of pathologists’ subjectivity. Any ideal prognostic or 
therapeutic biomarker should be performed easily with accurate 
and simple methods and have high sensitivity and specificity. 
From now on, the objectification of SALL4 expression is needed 
with further study.
In summary, we found that positive immunostaining of 
SALL4 is correlated with poor patient survival outcome in large 
and undifferentiated Korean HCC. SALL4 expression showed 
close relationship with clinical outcomes of HCCs in Korean 
patients. Further careful well-designed study for SALL4 stem 
cell marker as a biomarker for HCCs should be done with 
multinational studies for general application of SALL4.
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